Elizabeth A. Barrett is CEO at UroGen Pharma Ltd. (URGN). They have made 6 open-market trades across 1 company since 2019, most recently 2025-07-31.
CIK 0001764157
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $645K since 2019, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| URGN | 326,691 | $11.3M |
Shares reported on the most recent Form 4, priced at the 2023-02-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| URGN | SELL | 2022-01-31 | 2022-02-02 | $7.58 | $62K | -2.4% | -14.9% | -4.9% |
| URGN | SELL | 2022-01-04 | 2022-01-07 | $9.15 | $860K | -8.8% | -10.9% | -2.7% |
| URGN | BUY | 2020-12-14 | 2020-12-15 | $18.50 | $185K | -10.5% | +5.0% | -2.6% |
| URGN | BUY | 2019-11-21 | 2019-11-22 | $28.00 | $211K | +3.1% | +14.6% | +1.4% |
| URGN | BUY | 2019-11-20 | 2019-11-22 | $28.00 | $209K | +3.1% | +14.6% | +1.4% |
| URGN | BUY | 2019-11-15 | 2019-11-18 | $26.00 | $40K | +18.8% | +27.0% | +12.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.